AU2018317812C1 - Novel tetrazole compounds and their use in the treatment of tuberculosis - Google Patents
Novel tetrazole compounds and their use in the treatment of tuberculosis Download PDFInfo
- Publication number
- AU2018317812C1 AU2018317812C1 AU2018317812A AU2018317812A AU2018317812C1 AU 2018317812 C1 AU2018317812 C1 AU 2018317812C1 AU 2018317812 A AU2018317812 A AU 2018317812A AU 2018317812 A AU2018317812 A AU 2018317812A AU 2018317812 C1 AU2018317812 C1 AU 2018317812C1
- Authority
- AU
- Australia
- Prior art keywords
- tetrazol
- benzenesulfonamide
- hydroxyethyl
- methyl
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382574.6 | 2017-08-17 | ||
| EP17382574 | 2017-08-17 | ||
| PCT/EP2018/072205 WO2019034729A1 (en) | 2017-08-17 | 2018-08-16 | NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2018317812A1 AU2018317812A1 (en) | 2020-02-20 |
| AU2018317812B2 AU2018317812B2 (en) | 2021-04-15 |
| AU2018317812C1 true AU2018317812C1 (en) | 2021-08-26 |
Family
ID=59713960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018317812A Active AU2018317812C1 (en) | 2017-08-17 | 2018-08-16 | Novel tetrazole compounds and their use in the treatment of tuberculosis |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11072591B2 (enExample) |
| EP (1) | EP3668856B1 (enExample) |
| JP (1) | JP7410017B2 (enExample) |
| KR (1) | KR102661367B1 (enExample) |
| CN (1) | CN110997651B (enExample) |
| AU (1) | AU2018317812C1 (enExample) |
| CA (1) | CA3072854A1 (enExample) |
| CY (1) | CY1124577T1 (enExample) |
| DK (1) | DK3668856T3 (enExample) |
| ES (1) | ES2885573T3 (enExample) |
| HR (1) | HRP20211326T1 (enExample) |
| HU (1) | HUE055732T2 (enExample) |
| LT (1) | LT3668856T (enExample) |
| PL (1) | PL3668856T3 (enExample) |
| PT (1) | PT3668856T (enExample) |
| RS (1) | RS62267B1 (enExample) |
| SI (1) | SI3668856T1 (enExample) |
| SM (1) | SMT202100515T1 (enExample) |
| WO (1) | WO2019034729A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111184718A (zh) * | 2018-11-15 | 2020-05-22 | 鲁南制药集团股份有限公司 | 法罗培南在制备治疗初治病原学阳性肺结核药物中的用途 |
| CN115403533B (zh) * | 2021-05-28 | 2023-08-25 | 永康市第一人民医院 | 一种1-苯乙烯基-1,2,3-三氮唑化合物及其制备方法和应用 |
| CN116102483B (zh) * | 2021-11-09 | 2025-01-17 | 中国医学科学院药物研究所 | 取代吡咯-2,5-二酮类化合物及其制备方法和用途 |
| CN116726018A (zh) * | 2023-08-02 | 2023-09-12 | 上海市肺科医院（上海市职业病防治院） | 一种贝达喹啉、德拉马尼、氯法齐明和吡嗪酰胺的联用和应用 |
| CN117379430B (zh) * | 2023-10-11 | 2026-07-21 | 深圳市第三人民医院(深圳市肝病研究所) | 一种地拉韦啶的用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017066964A1 (en) * | 2015-10-22 | 2017-04-27 | Merck Sharp & Dohme Corp. | Oxazolidinone compounds and methods of use thereof as antibacterial agents |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ID24105A (id) | 1997-07-22 | 2000-07-06 | Shionogi & Co | Komposisi untuk mengobati atau mencegah glomerulopati |
| JP2010523599A (ja) | 2007-04-05 | 2010-07-15 | シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド | クリックケミストリーを使用した炭酸脱水酵素−ｉｘのための分子イメージングプローブの開発 |
-
2018
- 2018-08-16 HU HUE18755815A patent/HUE055732T2/hu unknown
- 2018-08-16 PL PL18755815T patent/PL3668856T3/pl unknown
- 2018-08-16 CA CA3072854A patent/CA3072854A1/en active Pending
- 2018-08-16 HR HRP20211326TT patent/HRP20211326T1/hr unknown
- 2018-08-16 JP JP2020508427A patent/JP7410017B2/ja active Active
- 2018-08-16 SM SM20210515T patent/SMT202100515T1/it unknown
- 2018-08-16 KR KR1020207007186A patent/KR102661367B1/ko active Active
- 2018-08-16 WO PCT/EP2018/072205 patent/WO2019034729A1/en not_active Ceased
- 2018-08-16 EP EP18755815.0A patent/EP3668856B1/en active Active
- 2018-08-16 AU AU2018317812A patent/AU2018317812C1/en active Active
- 2018-08-16 LT LTEPPCT/EP2018/072205T patent/LT3668856T/lt unknown
- 2018-08-16 RS RS20211076A patent/RS62267B1/sr unknown
- 2018-08-16 ES ES18755815T patent/ES2885573T3/es active Active
- 2018-08-16 SI SI201830348T patent/SI3668856T1/sl unknown
- 2018-08-16 DK DK18755815.0T patent/DK3668856T3/da active
- 2018-08-16 CN CN201880053320.XA patent/CN110997651B/zh active Active
- 2018-08-16 US US16/639,163 patent/US11072591B2/en active Active
- 2018-08-16 PT PT187558150T patent/PT3668856T/pt unknown
-
2021
- 2021-08-31 CY CY20211100770T patent/CY1124577T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017066964A1 (en) * | 2015-10-22 | 2017-04-27 | Merck Sharp & Dohme Corp. | Oxazolidinone compounds and methods of use thereof as antibacterial agents |
Also Published As
| Publication number | Publication date |
|---|---|
| PT3668856T (pt) | 2021-09-15 |
| CA3072854A1 (en) | 2019-02-21 |
| PL3668856T3 (pl) | 2021-12-13 |
| SI3668856T1 (sl) | 2021-11-30 |
| US20200231555A1 (en) | 2020-07-23 |
| KR102661367B1 (ko) | 2024-04-29 |
| BR112020003247A2 (pt) | 2020-08-18 |
| CN110997651B (zh) | 2023-01-03 |
| CN110997651A (zh) | 2020-04-10 |
| RS62267B1 (sr) | 2021-09-30 |
| LT3668856T (lt) | 2021-09-27 |
| RU2020110818A3 (enExample) | 2021-10-11 |
| KR20200041915A (ko) | 2020-04-22 |
| EP3668856B1 (en) | 2021-06-23 |
| CY1124577T1 (el) | 2022-07-22 |
| JP7410017B2 (ja) | 2024-01-09 |
| AU2018317812A1 (en) | 2020-02-20 |
| AU2018317812B2 (en) | 2021-04-15 |
| HUE055732T2 (hu) | 2021-12-28 |
| RU2020110818A (ru) | 2021-09-17 |
| ES2885573T3 (es) | 2021-12-14 |
| US11072591B2 (en) | 2021-07-27 |
| EP3668856A1 (en) | 2020-06-24 |
| HRP20211326T1 (hr) | 2021-11-26 |
| WO2019034729A1 (en) | 2019-02-21 |
| JP2020531425A (ja) | 2020-11-05 |
| DK3668856T3 (da) | 2021-09-20 |
| SMT202100515T1 (it) | 2021-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018317812B2 (en) | Novel tetrazole compounds and their use in the treatment of tuberculosis | |
| EP3880676B1 (en) | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer | |
| AU2018221812B2 (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
| EP3191478B1 (en) | Compounds and compositions as raf kinase inhibitors | |
| ES2791315T3 (es) | Agonistas triazoles del receptor APJ | |
| JP2021119140A (ja) | アミノ酸化合物および使用方法 | |
| JP6308504B2 (ja) | タンパク質キナーゼ阻害薬 | |
| AU2025204882A1 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
| EP1910360B1 (en) | Hiv reverse transcriptase inhibitors | |
| CA2899967A1 (en) | Biaryl amide compounds as kinase inhibitors | |
| CN107001329B (zh) | 作为激酶抑制剂的化合物和组合物 | |
| JP2018505903A (ja) | Ｇｄｆ−８阻害剤 | |
| WO2010109122A1 (fr) | Derives de nicotinamide, leur preparation et leur application en therapeutique comme anticancereux | |
| US12624034B2 (en) | Non-covalent modifiers of AKT1 and uses thereof | |
| WO2024178390A1 (en) | Covalent modifiers of akt1 and uses thereof | |
| WO2026090477A1 (en) | Helicase inhibitors and uses thereof | |
| RU2800930C2 (ru) | Новые производные тетразола и их применение в лечении туберкулеза | |
| BR112020003247B1 (pt) | Compostos de tetrazol, uso dos ditos compostos para o tratamento de infecção micobacteriana ou de doença causada pela mesma, composição farmacêutica e combinação que compreende os compostos | |
| RU2801140C2 (ru) | Соединения азалактама в качестве ингибиторов hpk1 | |
| CN121752559A (zh) | 吗啉促食欲素受体拮抗剂 | |
| CN121712766A (zh) | 吗啉促食欲素受体拮抗剂 | |
| OA20310A (en) | 2,3-dihydro-1H-pyrrolo[3,4-C] pyridin-1one derivatives as HPK1 inhibitors for the treatment of cancer. | |
| CN107108650A (zh) | 作为抗分枝杆菌剂的取代的1,2,3‑三唑‑1‑基‑甲基‑2,3‑二氢‑2‑甲基‑6‑硝基咪唑并[2,1‑b]噁唑及其制备方法 | |
| EA045220B1 (ru) | МОДУЛЯТОРЫ Cot И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| HK1227385B (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 10 MAY 2021 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 10 MAY 2021 |
|
| FGA | Letters patent sealed or granted (standard patent) |